DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2020-02-13

Last Posted Date: 2023-01-26

Lead Sponsor: AbbVie

Target Recruit Count: 534

Registration Number: NCT04267536

Locations: 🇩🇪
Rheumahaus Studien GbR, Potsdam, DE /ID# 218430, Potsdam, Brandenburg, Germany
🇩🇪
Stille, Hanover, DE /ID# 218429, Hannover, Germany
🇩🇪
Praxis K. Pagel /ID# 218714, Hoppegarten, Germany

and more 49 locations

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

Phase 1

Terminated

Conditions: Atopic Dermatitis

Interventions: Device: Wrist Actigraphy Device
Device: Sleep Headband

First Posted Date: 2020-02-10

Last Posted Date: 2022-02-15

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT04262791

Locations: 🇺🇸
PPD Clinical Research Unit /ID# 217010, Orlando, Florida, United States
🇺🇸
Acpru /Id# 217345, Grayslake, Illinois, United States
🇺🇸
Univ Rochester Med Ctr /ID# 217490, Rochester, New York, United States

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Phase 1

Completed

Conditions: Ulcerative Colitis (UC)
Crohn's Disease

Interventions: Drug: Risankizumab
Drug: Cytochrome P450 (CYP) Substrates

First Posted Date: 2020-02-05

Last Posted Date: 2024-07-01

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT04254783

Locations: 🇺🇸
University Clinical Research /ID# 216823, DeLand, Florida, United States
🇺🇸
Southern California Res. Ctr. /ID# 216257, Coronado, California, United States
🇺🇸
Clinical Trials of Texas, Inc /ID# 216277, San Antonio, Texas, United States

and more 3 locations

A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Completed

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2020-02-05

Last Posted Date: 2024-11-07

Lead Sponsor: AbbVie

Target Recruit Count: 51

Registration Number: NCT04253314

Locations: 🇷🇺
Hematology department State budgetary health care institution Volgograd region /ID# 229813, Volgograd, Volgogradskaya Oblast, Russian Federation
🇷🇺
Regional Clinical Hospital of Irkutsk /ID# 218570, Irkutsk, Russian Federation
🇷🇺
Clinical Medico-Sanitary Unit #1 /ID# 222502, Perm, Russian Federation

and more 7 locations

Flexible-Dose Trial in Early Parkinson's Disease (PD)

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Tavapadon

First Posted Date: 2020-01-10

Last Posted Date: 2025-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 304

Registration Number: NCT04223193

Locations: 🇦🇺
Macquarie Park, New South Wales, Sydney, New South Wales, Australia
🇺🇸
Fresno, California, Fresno, California, United States
🇺🇸
Boca Raton, Florida, Boca Raton, Florida, United States

and more 48 locations

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)
HIV-1
HIV Infection

Interventions: Drug: Placebo
Drug: ABBV-181

First Posted Date: 2020-01-10

Last Posted Date: 2023-03-09

Lead Sponsor: AbbVie

Target Recruit Count: 41

Registration Number: NCT04223804

Locations: 🇺🇸
Franco Felizarta, Md /Id# 215721, Bakersfield, California, United States
🇺🇸
Ruane Clinical Research Group /ID# 224866, Los Angeles, California, United States
🇺🇸
Quest Clinical Research /ID# 215796, San Francisco, California, United States

and more 20 locations

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2019-12-30

Last Posted Date: 2024-10-29

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT04214028

Locations: 🇯🇵
Kariya Toyota General Hospital /ID# 239046, Kariya-shi, Aichi, Japan
🇯🇵
Nagoya City University Hospital /ID# 238745, Nagoya shi, Aichi, Japan
🇯🇵
Meijo Hospital /ID# 250955, Nagoya-shi, Aichi, Japan

and more 51 locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Phase 3

Completed

Conditions: Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Paclitaxel
Drug: Mirvetuximab Soravtansine
Drug: Topotecan
Drug: Pegylated liposomal doxorubicin

First Posted Date: 2019-12-24

Last Posted Date: 2025-01-07

Lead Sponsor: AbbVie

Target Recruit Count: 453

Registration Number: NCT04209855

Locations: 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

and more 210 locations

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Leukemia (SLL)
Cancer

First Posted Date: 2019-12-13

Last Posted Date: 2023-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT04198415

Locations: 🇯🇵
Nagoya City University Hospital /ID# 240820, Nagoya shi, Aichi, Japan
🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 239524, Nagoya-shi, Aichi, Japan
🇯🇵
Aso Iizuka Hospital /ID# 221140, Iizuka-shi, Fukuoka, Japan

and more 99 locations

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-368
Drug: Tilsotolimod
Drug: Nab-paclitaxel
Drug: ABBV-181

First Posted Date: 2019-12-12

Last Posted Date: 2023-02-27

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT04196283

Locations: 🇺🇸
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
🇺🇸
Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy